A inform poster actually picked this recently in a top rated post............"Based on the observed reduction in mortality and morbidity in this Phase 3 trial, Mesoblast intends to meet with the FDA to discuss a potential approval pathway".
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-8
-
- There are more pages in this discussion • 284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
-0.015(0.94%) |
Mkt cap ! $2.012B | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.59 | $1.53 | $9.037M | 5.803M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 28982 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 27600 | 3 |
View Market Depth
| Last trade - 16.10pm 09/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |